chrisvoncsefalvay/vaers-outcomes huggingface dataset:
pt recv vax 13APR98 210PM & was given 2 tab ibuprofen to promote comfort;14APR98 955AM c/o arm & backache;temp was taken;temp 98.4;14APR98 pt c/o numbness/tingling in arm & back;MD contacted regarding poss neuro complications;allerg rxn;
Mom states pt had t104 R 12MAR92 & stayed high; t101.6 R today; pt was limp all weekend & jsut lies around; pt eating but not drinking fluids much; pt given APAP & cool baths; 16MAR93 seen by MD dx w/bronchitis;
PATIENT REPORTS HE HAS HAD PAIN IN HIS RIGHT ARM EVER SINCE RECEIVING HIS SECOND DOSE OF PFIZER VACCINE. THIS HAS BEEN OVER 7 MONTHS.
I still have swollen arm and i had 4 days of strong sweat. The application site still has a slight red spot.; I still have a swollen arm; I still have swollen arm and i had 4 days of strong sweat.; The application site still has a slight red spot; This is a spontaneous report from a contactable consumer (patient). A 34-years-old female pregnant patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot/Batch number: unspecified, Pfizer), via an unspecified route of administration in left arm on 08Jun2021 at 16:45 (at the age of 34-years-old) as unknown, single for covid-19 immunization. The patient medical history was none. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not have any known allergies. The patient did not receive any other medication in 2 weeks. The patient did not receive any other vaccines within 4 weeks. On 09Jun2021, the patient stated that she still had swollen arm and had 4 days of strong sweat. The application site still had a slight red spot. The mother reported she became pregnant while taking bnt162b2. The mother was 24 Weeks pregnant at the onset of the event. The mother was due to deliver on 29Sep2021. The patient did not receive ant treatment for the events. The clinical outcome for the event was not recovered for events except for event exposure during pregnancy which was unknown.  Information on the lot/batch number has been requested.  Amendment- This follow up is being submitted to amend previously reported information:To delete classification At Risk from general tab.
2/01/2023 Sinus and nasal congestion intensified. 2/6 I went to see the doctor, Rapid COVID-19 test. Positive. Doctor proscribed Paxlovid, and to treat symptomatically with Nasacort. Symptoms did not diminish and have provided a round of antibiotics to treat a secondary sinus infection, but symptoms remain to time of reporting.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On an unknown date during 2016, the patient was inoculated with the ZOSTAVAX (lot number, dosage and route of administration not provided), as recommended for routine adult health maintenance and for the prevention of shingles. The ZOSTAVAX did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster. On an unknown date later in 2016, the patient was treated for a vesicular outbreak, which was diagnosed as herpes zoster, or shingles. The outcome of the events is unknown. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
fever, extreme weakness, pain in vaccine site travelling along my back and neck to the other arm, body aches, bad headache, large red and hot area on vaccine site
low grade fever with temperature 100.7F; bad muscle pain; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (low grade fever with temperature 100.7F) and MYALGIA (bad muscle pain) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 07-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-May-2021, the patient experienced PYREXIA (low grade fever with temperature 100.7F) and MYALGIA (bad muscle pain). The patient was treated with PARACETAMOL (TYLENOL) at a dose of 500 milligram. At the time of the report, PYREXIA (low grade fever with temperature 100.7F) and MYALGIA (bad muscle pain) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-May-2021, Body temperature: 100.7 (abnormal) 100.7F.   No concomitant medication was provided.
Gastrointestinal  upset: stomach cramps like gas. Took GasX but didn't help.  Entire abdomen area felt crampy and inflamed.  Stomach cramps so strong couldn't sleep.  Had diarrhea for 5 days.  I had a positive case of Covid at the end of December 2020.  Had headache for one day. The symptoms after the vaccine was 100 times worse than the actual covid symptoms for me.
severe migraine, fever, chills, vomiting for 6 hrs.  smell taste of sulfur that has not stopped and is ongoing
Patient called the pharmacy and spoke to me as the pharmacist on duty. He was reporting shoulder pain with limitation of movement along with range after he got his shot on 12-07-2022.  I asked him to show up to the pharmacy so I can look at the injection site. I noticed no swelling no bruising but he was complaining of pain. He told me he was using Voltaren Gel and Tylenol and that he is going to do MRI on that shoulder. I told him that we are going to follow up with him about the update of the pain level.
Information has been received from a medical assistant referring to unspecified patients of unknown age and gender. Concurrent or historical condition were not provided. On unknown dates the patients received improperly stored doses of GARDASIL 9 (lot # M004116 with expired date of 12-OCT-2017, lot # L024993 with expired date of 17-OCT-2017, dose and route unknown). Concomitant therapy was not provided. The vaccines were stored under 33F for 1 hour (6 cycles, 10 minutes each cycle). Storage temperature had been back in range. There was no previous temperature excursion. Data logger was involved. No adverse effects reported. This is one of 2 reports received from the same reporter. Additional information has been requested.
Vaccine booster administered on 11/12/2021, expiration date was 11/7/202.  Mistook expiration date to be 11/17/2021.  No adverse event or outcome to recipient.
On 3/14/2021, one day after her second Moderna vaccination, my sister brought my mother to the hospital due to mild confusion, fever, rigors, and myalgia.   She was given prescriptions for doxycycline hyclate 100 mg  oral capsule, Tylenol Extra Strength 500mg oral tablet, and Ibuprofen 600 mg oral tablet.  She was in the ER for almost 4 hours and discharged.
vaccine was frozen rather than refrigerated. dose was given to patient. no symptoms reported. revaccination offered.
Extreme exhaustion, low grade fever, achy joints/muscles, severe headache, lightheaded
Pt tested positive for COVID on 9/24/21 s/p 2 doses of Pfizer (last dose 5/10/21); was admitted to hospital on 10/4/21. Of note, pt is immunocompromised w/ Lupus receiving tx w/ Rituxan
client complained of itching all over and nasal congestion Epipen 0.3mg given Injection and benadryl 25mg po
Patient has had 3 doses of Moderna COVID vaccine(on 2/18/21, 3/18/21, and 11/17/21), and was hospitalized for COVID and INfluenza A on 12/19/2021
swollen lymph node on left side near collar bone; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 43 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 10Mar2021 10:30 (Lot number: EN6207) at the age of 43 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "celiac disease" (unspecified if ongoing); "mild-moderate sleep apnea" (unspecified if ongoing); "gluten allergy" (unspecified if ongoing). Concomitant medication(s) included: FINASTERIDE. The following information was reported: LYMPHADENOPATHY (non-serious) with onset 23Mar2021 18:00, outcome "not recovered", described as "swollen lymph node on left side near collar bone". Therapeutic measures were not taken as a result of lymphadenopathy.  Additional information: The patient had not received any other vaccines within 4 weeks and had not been diagnosed with COVID-19 prior vaccination. Since the vaccination the patient had not been tested for COVID-19.  No follow-up attempts are possible. No further information is expected.
Chills no temp and Fatigue Narrative:  pt spoke with Triage nurse on 2/12 with c/o increased fatigue and chills. several days following #2Covid vaccine. Temp 95.6. No other symptoms reported.
lymphodema? redness, whelpping, heat to touch, soreness along interior biceps area. several inches from injection site.
After the patient left the clinic while completing the vaccination record paperwork, this RN realized the Bexero  vaccine administered to the patient had an expiration date of 07/31/22. Supervisor was immediately notified.  Call placed to Glaxo Smith-Kline Medical Information to find out vaccine viability  period past the expiration date.  Spoke to Medical Information Scientist who informed this RN that although GSK does not recommend, and the CDC has not evaluated the immunogenicity or safety of giving an expired vaccine, an in-house stability analysis and potency testing study shows that when stored under proper conditions and temperatures, the Bexero vaccine remains within approved specification up to 30 days past the expiration date.  The Bexero Vaccine given had been continuously stored in the proper conditions and temperatures prior to being administered.  This RN requested writtten documentation of information received over the telephone, and received the information via email.    No adverse reactions were reoprted by the patient or parent.
Pain, redness 3" x 6". Feels feverish. (Pt. reported pain at time of injection). Rx KEFLEX 500mg QID x 10 days. Medrol Dose Pack.
28nov89 pt vax Hepta B. pt ex. pain inject site pt  2nd vax hepta B on 28dec89. pt ex prolonged pain and tenderness at inject site which continued for 2 days to 1 week. pt recovered.
LIP SWELLING 1 hour post vaccination subsided after Benadryl 50mg adm. Narrative:
Initial unsolicited report received from a healthcare professional in the on 11-May-2018. This case involves a female patient, who was vaccinated once with 0.5 ml FLUZONE QUADRIVALENT via intramuscular route (batch number, expiry date not reported) on an unknown date. Patient's medical history and concomitant medications were not reported. On an unknown date, following the vaccination, the patient had Bell's Palsy. Lab test and corrective treatment was not reported. On an unknown date, patient recovered from the event. Upon internal review the case was considered as serious because of important medical event: Bell's Palsy. Documents held by sender: none. Sender's Comments: Patient developed Bell's palsy after vaccination with FLUZONE. Time to onset is unknown. The event is listed with the vaccine. Further information regarding vaccination details (vaccination date), time to onset, medical history as well as concurrent condition during vaccination, previous vaccination and tolerance, laboratory investigations excluding alternative etiologies for the reported events are needed to fully assess this case. Based upon the given information the role of the vaccine cannot be assessed.
Patient was supposed to receive bivalent booster but was mistakenly given monovalent vaccine due to a look-alike error.
Vaccine administered after temparature excursion; No additional AEs; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. Information regarding the patient's pertinent medical history, historical drugs, concurrent conditions, drug reactions or allergies and concomitant therapies were not provided.   On 21-DEC-2021 the patient was vaccinated with measles, mumps, rubella and varicella (Oka-Merck) virus vaccine live recombinant human albumin (rHA) (PROQUAD) subcutaneous, 0.5 milliliter(ml), after temperature excursion (product storage error) (lot number U019286, expiration date 15-DEC-2022 ; vaccination scheme, and anatomical site of vaccination were not reported) for prophylaxis.    The vaccine underwent a temperature excursion of 6.8 Fahrenheit (F) for 8 hours 5 minutes. There was no previous temperature excursion.   No additional adverse events (no adverse event) or product quality complaints were reported.
Patient was only given the Diluent and not the actual Immunization. Patient will come in to the clinic to receive the vaccine.  No adverse effects.
Information has been received from a health professional concerning a 13-year-old male who on 24-JUL-2007 was vaccinated subcutaneously in the left arm with is second dose of varicella virus vaccine live (Oka/Merck) (lot# 654282/0776U). On 26-JUL-2007, the patient experienced a red, swollen area at the injection site. No medical attention was sought. No outcome was reported. This is one of several reports from the same reporter. Additional information has been requested.
2 days post vax small swelling, 5x5mm @ inj site lt thigh surrounded by erythema 8x9cm w/itching 3 days post vax;afeb;
mom called evening of 22PAr & swelling @ inj site was seen on 23APR99 w/large area of swelling sl warm to touch& some redness which was fading per mom;
h/a, nausea, malaise-began day p/vax lasted 2 days; w/dose #2 same sx-more sever h/a-began 2 days p/vax-lasted 1 wk;
This case was reported by a pharmacist via call center representative and described the occurrence of allergy in a patient who received FLUARIX QUADRIALENT (2018-2019 season) for prophylaxis. On an unknown date, the patient received FLUARIX QUADRIALENT 2018-2019 season at an unknown dose. On an unknown date, less than a year after receiving FLUARIX QUADRIALENT 2018-2019 season, the patient experienced allergy. On an unknown date, the outcome of the allergy was unknown. It was unknown if the reporter considered the allergy to be related to FLUARIX QUADRIALENT t 2018-2019 season. Additional details were provided as follows: The age at vaccination was not reported. The pharmacist stated that the patient reported allergy after receiving FLUARIX. The reporter did not have patient demographics, lot number and expiration date or the specific symptoms that were experienced by the patient. The reporter stated that the patient was consulting an allergist.
Case received from a consumer who is the patient's mother on 05 September 2013: A male patient (age not reported), medical history and concomitant medication were unknown, had received a dose of Meningococcal vaccine from unknown manufacturer (Lot number, route and anatomical site of administration were not reported) on an unspecified date. On an unspecified date after vaccination, the patient fainted and was taken to the emergency room. Laboratory details and corrective medication was not reported. The patient's outcome was unknown.
104F fever for 24 hours. Extreme lightheadedness, to the point of not being able to walk more than 10 feet without a break.
Extreme fatigue greater than 24 hours, sleepiness greater than 24 hours, soreness at injection site.
Within one minute of vaccine, my daughter had a Tonic, Clonic Seizure, and fell off exam table while waiting for wait time protocol. She received a concussion, and blunt force trauma.  MD immediately sent her to ER for an MRI which hospital refused to perform.
Fever, body  aches next post vaccine.  Treatment included Tylenol and Motrin with complete resolution of symptoms the night of day 2 and day 3 post vaccine. Symptoms did not interfere with ADLs.
After about two weeks of my booster shot,  I have been experiencing hives with itching and some pain . The hives appear randomly in different parts of the body. They disappear after about 20-30 mins. The hives are itchy and sometimes painful. This has been happening close to a week now
tiny hives starting inside of knees on both legs-spreading to thighs; This is a spontaneous report from a contactable consumer. A 63-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number was not reported), via an unspecified route of administration on 07Mar2021 08:30 AM as a single dose for covid-19 immunisation. The patient medical history included allergies to sulpha drugs, shellfish, gluten. Concomitant medication included levothyroxine daily. It was reported that, the patient had tiny hives starting inside of knees on both legs - spreading to thighs 3-4 hours after injection on 07Mar2021 12:00 PM. No therapeutic measures were taken. The outcome of the event was not recovered at the time of report.  No Follow-up attempts are possible. Information about lot/batch cannot be obtained.
multiple outbreaks of a painful itchy rash and herpes zoster; multiple outbreaks of a painful itchy rash and herpes zoster; multiple outbreaks of a painful itchy rash and herpes zoster; The information was received from a lawyer refers to a patient of unknown age and gender. The patient's concurrent conditons, historical conditions and concomitant therapy were not reported. On or about 26-SEP-2017, patientf was inoculated with zoster vaccine live (ZOSTAVAX) vaccine for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after receiving zoster vaccine live (ZOSTAVAX) vaccine, patient suffered multiple outbreaks of a painful itchy rash and herpes zoster. As a result of these symptoms, patient  was seen and treated by medical providers and is still under their care. As a direct and proximate result of zoster vaccine live (ZOSTAVAX) vaccine, patient's symptoms have resulted in physical limitations not present prior to using the product. Patient also experience mental and emotional distress due to resulting physical limitations and seriousness of patient's condition.As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), patient sustained severe and permanent personal injuries. Further, as a tragic consequence of company's wrongful conduct, patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of company's conduct, patient have suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The events were considered to be related to zoster vaccine live (ZOSTAVAX).      On 26-SEP-2017 the patient was vaccinated with zoster vaccine live (ZOSTAVAX), unknown for routine health maintenance and prophylaxis.       On an unknown date the patient experienced rash pruritic (disability), herpes zoster (disability) and rash (disability).    The outcome of herpes zoster, rash and rash pruritic is unknown.   The reporter considered rash pruritic, herpes zoster and rash to be related to Zoster Vaccine Live(ZOSTAVAX).     {Additional information has been requested. / Additional information is not expected.}
This spontaneous report as received from a certified medical assistant refers to a patient of unknown age and gender. On 13-MAR-2014, the patient was inadvertently vaccinated with a dose of M-M-R II (lot # 0411AE, HSA, dose and route not reported) that had expired on 27-FEB-2014. No adverse effects were reported. Additional information has been requested.
Constant Ringing, ( Tinnitus) primarily in right ear, started 14 days after first vaccination. Has continued for 4 weeks.
This case was reported by a consumer via call center representative and described the occurrence of headache in a 70-year-old male patient who received SHINGRIX for prophylaxis. On 24th May 2018, the patient received the 1st dose of SHINGRIX. In May 2018, 8 hrs after receiving SHINGRIX, the patient experienced headache. On an unknown date, the patient experienced muscle pain. On an unknown date, the outcome of the headache and muscle pain were recovered/resolved. It was unknown if the reporter considered the headache and muscle pain to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The reporter reported headaches and body ache after both doses. The caller stated that after his first shot of SHINGRIX he experienced a headache about 8 hours after the shot which resolved by the third day.  He also experienced a little bit of muscle ache which lasted no more than 3 days. This case has been linked with US2018GSK157252 , reported by the same reporter for the same patient.
This is a very pleasant white male does have a history of prior tobacco abuse, drinks socially, has a history of sleep apnea but does not wear CPAP who is vaccinated for Covid x2 although its been many many months, who presents after having some upper respiratory symptoms that started about 4 days ago to the best of his knowledge and then today did have some diarrhea and is starting to feel short of breath.  He did have an outpatient Covid test up and was positive.  He called his primary doctor to discuss the fact that he was feeling short of breath specially with exertion and Nate advised him to coming to the emergency department.  He has no history of heart disease denies any chest pain.  Denies any fever Associated Symptoms: cough, diarrhea, fatigue, shortness of breath, URI symptoms
COVID-19; COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 48-year-old male patient received BNT162b2 (BNT162B2), on 26May2021 as dose 2, single (Batch/Lot number: unknown) at the age of 47 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 27Oct2022, outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This 15 year old patient presented to vaccine clinic with parents and younger sibling on 1/26/22. Younger sibling was in age category 5-11 years old and received the pediatric 5-11 year old Pfizer COVID vaccine. This 15 year old patient was inadvertently given the pediatric 5-11 year old dose. Patient tolerated the vaccine well. No adverse events. Mother informed of the vaccination error. Medical director was informed and advised no further action necessary except to finish the primary series in 3 weeks with the age appropriate formulation.